Journal
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Volume 343, Issue 3, Pages 540-546Publisher
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/jpet.112.191759
Keywords
-
Categories
Funding
- National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases [RC2-AR058962]
- National Institutes of Health National Institute on Aging [1P01-AG039355-01A1]
- Missouri Life Sciences Research Board
- Department of Health Services-Clay County Senior Services
Ask authors/readers for more resources
Sarcopenia remains largely undiagnosed and undertreated because of the lack of a universally accepted definition, effective ways to measure it, and identification of the outcomes that should guide treatment efficacy. An ever-growing number of clinicians and researchers along with funding and regulatory agencies have gradually recognized that sarcopenia is a human condition that requires both prevention and treatment. In this article, we review sarcopenia and its common and less known pharmacological treatments, attempt to define sarcopenia in its broader context, and present some new ideas for potential future treatment for this devastating condition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available